A2AR blockade reduces CD4+ Foxp3+ Tregs in HNSCC mouse model. A2AR blockade enhances the anti-tumor response of CD8+ T cells in HNSCC mouse model. Here, FOXP3 is linked to head and neck squamous cell carcinoma.